Latest Shareholder Value News

Waratah Minerals has reported significant progress in its Spur Gold-Copper Project, extending gold zones with over 4,700 metres drilled in the December quarter. Strategic board appointments signal a new phase for the company as it positions itself for further exploration success.

Nelson Resources bolstered its balance sheet with a $2.3 million placement and appointed Dr Louis Bucci as Executive Director, setting the stage for renewed exploration at its Fortnum and Yarri gold projects in early 2025.

Algorae Pharmaceuticals reports robust progress in its drug development pipeline, highlighted by promising preclinical results for cardiovascular and dementia candidates and significant AI platform enhancements.

Litchfield Minerals has confirmed a substantial expansion of the Oonagalabi base metal system, extending its geochemical footprint beyond 3km. The company is gearing up for an aggressive 2025 exploration campaign, including geophysical surveys and drilling, despite potential weather-related delays.

Syntara Limited has reported encouraging interim Phase 2 trial results for its lead drug candidate SNT-5505 in myelofibrosis, alongside a successful A$15 million capital raise to advance multiple clinical programs.

Imugene Limited has secured A$20 million through convertible notes as part of a broader A$46 million capital raise, aiming to advance its promising immuno-oncology pipeline.

Horizon Minerals reports a $14 million placement and a proposed merger with Poseidon Nickel, alongside key production milestones including the first gold pour at Boorara and a prefeasibility study at Penny's Find.

Gold Road Resources delivered record gold production and free cash flow in the December 2024 quarter, strengthening its balance sheet and setting ambitious 2025 guidance.

Gold Road Resources delivered record gold production and sales in the December 2024 quarter, alongside robust cash flow growth and promising exploration advances, positioning the company for an ambitious 2025.

Parabellum Resources reports a capital return from its Temarise investment and a strategic board reshuffle, while progressing exploration plans across its New South Wales projects.

Mighty Kingdom Ltd has received $1.809 million in tax rebates, significantly enhancing its capital flexibility as it refines operations and explores future growth opportunities.

Anatara Lifesciences has been granted a key Australian patent for its GaRP gastrointestinal health product, reinforcing its intellectual property portfolio ahead of pivotal clinical trial results expected in March 2025.